SlideShare a Scribd company logo
1 of 74
Download to read offline
THALASSEMIA
WORLD THALASSEMIA DAY-MAY 8
Dr. VENKATESH
OBJECTIVES
To know :
• Basic features of thalassemia syndromes
• Transfusion protocols in thalassemia
• Chelation therapy in thalassemia
• Supportive care in thalassemic patients
• Follow-up guidelines
• Hemtopoitic Stem cell transplantation
• Future aspects.
DEFINITION
Thalassemia is a group of inherited
disorders of hemoglobin synthesis
characterized by a reduced or absent
one or more of the globin chains of
adult hemoglobin.
They characterised by varying degrees
of ineffective hematopoiesis and
increased hemolysis
ICD classification: D-56
HEMOGLOBIN A
 Fetal Hemoglobin (2 alpha, 2 gamma)
 Hemoglobin A2 (2 alpha, 2 delta)
 Small amounts in body
α
αβ
β
Copyright ©1997 BMJ Publishing Group Ltd.
NORMAL HUMAN HAEMOGLOBINS
Haemoglobin Structural
formula
Adult Hb-A 2 2 97%
Hb-A2 2 2 1.5-3.2%
Fetal Hb-F 2 2 0.5-1%
Embryonic Hb-Gower 1 2 2
Hb-Gower 2 2 2
Hb-Portland 2 2
GENETIC TYPES OF THALASSEMIA :
There are two basic groups of thalassemia.
 Alpha (  )Thalassemia
In alpha-thalassemia, the alpha genes are deleted;
loss of one gene (α-/α) or both genes (α-/α-) from each
chromosome 16 may occur, in association with the
production of some or no alpha globin chains
 Beta (  )Thalassemia
In beta-thalassemia defective production usually
results from disabling point mutations causing no (β0) or
reduced (β-) beta chain production.
CHROMOSOMES
 Thalassemia is inherited as an autosmal recessive
disease.
EPIDEMIOLOGY
 Recent data indicate that about 7% of the world
population is carrier of hemoglobin disorder.
 About 100,000 children are born every year world
over with the homozygous state for thalassemia.
There are around 65,000 - 67,000 thalassemia
patients in our country.
 In India prevalence of this gene varies, 1-17 %
(3.3%).
 Common in certain Communities like sindhis,
punjabis, khatris, khukrajas, bhanushalies, baniyas,
lohanas, kuchies, mahars, kolies, agries, goudas,
lingayats .
ALPHA THALASSEMIA
 Alpha Thalassemia: deficient/absent alpha subunits
 Excess beta subunits
 Excess gamma subunits newborns
 Tetramers formed:
 Hemoglobin H adults
 Hemoglobin Bart’s newborns
 types:
 Silent Carrier
 Trait (Minor)
 Hemoglobin H Disease
 Hydrops fetalis(Hb Bart’s)
GENETIC BASIS OF ALPHA THALASSEMIA
 Encoding genes on chromosome 16 (short arm)
 Each cell has 4 copies of the alpha globin gene
 Each gene responsible for ¼ production of alpha globin
 4 possible mutation states:
 Loss of ONE gene  silent carrier
 Loss of TWO genes  thalassemia minor (trait)
 Loss of THREE genes  Hemoglobin H
 Accumulation of beta chains
 Association of beta chains in groups of 4  Hemoglobin H
 Loss of FOUR genes  Hemoglobin Barts
 NO alpha chains produced ∴ only gamma chains present
 Association of 4 gamma chains  Hemoglobin Barts
CLASSIFICATION & TERMINOLOGY
ALPHA THALASSEMIA
• Normal /
• Silent carrier - /
• Minor -/-
--/
• Hb H disease --/-
• Barts hydrops fetalis --/--
CLINICAL OUTCOMES OF ALPHA THALASSEMIA
 Silent carriers
• asymptomatic
• “normal”
 Alpha Thalassemia trait
• no anemia /mild anemia
• microcytosis
-unusually small red blood cells due to fewer Hb in RBC
 Hb H disease
• microcytosis & hemolysis (breakdown of RBC)
- results in severe anemia
• bone deformities
• splenomegaly (enlargement of spleen)
• “severe and life threatening”
• Golf ball inclusions on micrscopy
CLINICAL OUTCOMES OF ALPHA THALASSEMIA
 Bart’s Hydrops fetalis
• Hb Bart’s
• fatal hydrops fetalis
- fluid build-up in fetal compartments, leads to
death occurs in utero
BETA THALASSEMIA
 Beta Thalassemia: deficient/absent beta subunits
 Commonly found in Mediterranean, Middle East, Asia,
and Africa
 Three types:
 Minor
 Intermedia
 Major (Cooley anemia)
 asymptomatic at birth as HbF functions
GENETIC BASIS OF BETA THALASSEMIA
 Encoding genes on chromosome 11 (short arm)
 Each cell contains 2 copies of beta globin gene
 beta globin protein level = alpha globin protein level
 Suppression of gene more likely than deletion
 2 mutations: beta-+-thal / beta-0-thal
 “Loss” of ONE gene  thalassemia minor (trait)
 “Loss” of BOTH gene  complex picture
 2 beta-+-thal  thalassemia intermedia / thalassemia
major
 2 beta-0-thal  thalassemia major
 Excess of alpha globin chains
CLASSIFICATION & TERMINOLOGY
BETA THALASSEMIA
• Normal /
• Minor /0
/+
• Intermedia 0/+
+/+
• Major 0/0
+/
CLINICAL OUTCOMES OF BETA THALASSEMIA
 Beta Thalassemia minor (trait)
• asymptomatic
• microcytosis
• minor anemia
• Elevated HbA2 >3.4%
 Beta Thalassemia intermedia .
• symptoms similar to Cooley Anemia but less severe
 Beta Thalassemia major (Cooley Anemia)
• most severe form
• moderate to severe anemia
• intramedullary hemolysis (RBC die before full
development)
• peripheral hemolysis & splenomegaly
• skeletal abnormalities (overcompensation by bone
marrow)
• congestive heart failure,pulmonary hypertension
PATHOPHYSIOLOGY
Disturbance of ratio between Alpha & non
alpha globin chain synthesis then absent or
decrease production of one or more globin
chains
Formation of abnormal Hb structures
Ineffective erythropoiesis
Excessive RBCs Destruction
Iron Overload
Extra-medullary hematopoiesis
PATHOPHYSIOLOGY..CONT..
SIGNS & SYMPTOMS
 Beta Thalassaemia Minor :
Usually no signs or symptoms
except for a mild persistent anemia not responding
to hematinics.
 BetaThalassaemia Major : manifests after 6 months
1. Pallor- fatigue, irritability
2. Growth retardation.
3. Recurrent infections
4. Bony abnormalities specially of the facial
bones,hemolytic facies, caput quadtratum
5. Enlarged spleen and liver.
6. Delayed sexual development
7. Features of complications .
THALASSEMIA COMPLICATIONS
 Complications can be grouped as
(1) transfusion-transmitted infections,
(2) transfusional iron overload,
(3) toxicities of iron chelation therapy, and
(4) bacterial infections
COMPLICTIONS ..CONT..
 Cardiac complications
 Liver complications
 Endocrine complications
 Bone complications
 Other complications
 Infections: yersinia,parvovirus B19
 Dental Complications
 Growth retardation
 Leg ulcers
CARDIAC COMPLICATIONS
 Cardiac dysfunction(both systolic and diastolic
dysfuction)
 Arrhythmias
 Ferritin greater than 2500 mg/L or a liver iron
concentration > 15 mg Fe/g dry weightis associated
with high risk of cardiac death in thalassemia
 ferritin and liver iron may not correlate with cardiac
iron load, cardiac iron can be specifically and
reproducibly measured using cardiac MRI T2*.
Cardiac MRI T2* less than 20 ms correlates with a
progressive and significant decline in LVEF
CARDIAC COMPLICATIONS CONT..
 Monitoring: 6 monthly cardiac physical examination,
cardiac function yearly starting at age of 10 years, if
history suggestive of arrhythmias ECG, 24-hour
Holter monitoring should be done.
 Chelation therapy to reduce high iron load lowers
the likelihood of developing cardiac dysfunction
CARDIAC COMPLICATIONS..CONT
Cardiac MRI T2 Cardiac iron load Cardiac function intervention
values greater
than 20 ms
not usually
associated with
significant iron load
not usually
associated with
cardiac dysfunction
compliance and
importance of
chelation stressed
values between 10
and 20 ms
significant cardiac
iron deposition
a risk of eventual
cardiac
decompensation
more aggressive
chelation program
should be
implemented
values < 10 ms Very high cardiac
iron load
significant risk of
more immediate
cardiac
decompensation
without aggressive
Aggressive
chelation therapy
should be started
immediately and
cardiac function
CARDIAC COMPLICATIONS..CONT
 Where cardiac MRI T2* is not available, • chelation
decisions should be based on ferritin, LIC and
cardiac function assessment
 Patients with ferritin > 2500 mg/ml and LIC >15g
Fe/g dry weight should be chelated more
aggressively.
 those with ferritin < 2500 mg/ml and LIC 7 – 15 g
Fe/g dry weight should have chelation adjusted
accordingly and compliance encouraged.
 Cardiologic intervention and management for heart
failure and arrhythmia should follow cardiology
standards apart from aggressive chelation
LIVER COMPLICATIONS
 includes- transfusion-related viral hepatitis
(Hepatitis B, C), iron overload, drug toxicity, and
biliary disease due to gallstones.
 Liver enzymes should be monitored routinely.
 Liver iron concentration should be monitored
routinely and chelation therapy initiated and
adjusted to reduce complications of iron overload.
 In the presence of elevated liver iron, liver fibrosis,
and cirrhosis may be accelerated by alcohol, liver-
toxic drugs, and untreated viral hepatitis, Limit such
exposure.
ENDOCRINE COMPLICATIONS
 Iron overload is responsible for dysfunction of many
of endocrine glands like thyroid, parathyroid
pituitary gland, gonads and pancreas.
 These include-
 short stature (34%),
 delayed puberty, hypogonadotropic hypogonadism (35
– 55%),
 hypothyroidism (10%),
 hypoparathyroidism (4%), and
 diabetes mellitus (5.6 – 20%)
ENDOCRINE COMPLICATIONS -
INTERVENTIONS
 Short stature-
 The diagnosis of growth hormone deficiency, other
hormonal or nutritional deficiencies or deferoxamine
toxicity should be considered
 Growth hormone stimulation testing should be done
and, if indicated, growth hormone therapy started
 Hypothyroidism
 TSH levels should be measured annually beginning at
12 years of age since hypothyroidism often develops
after adolescence.
 Hypothyroidism should be treated with thyroid hormone
replacement.
ENDOCRINE COMPLICATIONS -
INTERVENTIONS
 Impaired Glucose Tolerance and Diabetes
 Improvement of iron load with adequate combination
chelation therapy may decrease insulin resistance and
decrease glucose intolerance
 Impaired glucose tolerance and diabetes should be
managed as per diabetes protocols with emphasis on
glycemic control, diet, exercise, and management of
complications.
ENDOCRINE COMPLICATIONS -
INTERVENTIONS
 Delayed Puberty and Hypogonadism
 most common endocrine complication
 all children should be assessed yearly from the age of 10
years
 All patients with delayed puberty or hypogonadism should
receive appropriate investigations including bone age and
hormonal assessments, hormonal replacement therapy, and
subsequent follow-up by an endocrinologist
 Hypoparathyroidism
 All patients over the age of 12 years should have calcium and
phosphate levels checked at least every 6 months.
 If these are abnormal, parathyroid hormone level should be
measured. Hypoparathyroidism should be managed as per
endocrine standards
BONE COMPLICATIONS
 Bone disorders are common and multifactorial in
patients with thalassemia .
 Related to inadequate transfusion, iron-overload,
over-chelation, and other endocrine factors
contribute to the development of osteopenia and
osteoporosis
 Interventions:
 Adequate blood transfusions
 Adequate chelation therapy should be maintained
 No Over-chelation
 Hormone replacement therapy
 Calcitonin,bisphosphonates
 Diet rich in calcium and vitamin D
HYPERSPLENISM- SPLENECTOMY
 Indictions of splenectomy
 An increase in the yearly requirement of packed cells
more than 1.5 times the basal requirement, i.e. packed
cell 200 to 220 cc per kg/ year.
 Massive splenic enlargement posing risk of splenic
rupture, or when it is associated with left upper
quadrant pain or erly satiety
 Presence of leukopenia or thrombocytopenia due to
hyperspleenism
 Splenectomy should be delayed till the patientis 5
years of age as there is risk of overwhleming sepsis
below this age
 Risk of post-splenectomy serious infections can be
reduced by:
 Immunization against pneumococcal, meningococcal,
and Hib and salmonella typhi infection atleast 3 weeks
before splenectomy
 Chemoprophylaxis with oral penicillin,
 125 mg twice daily for children upto 2 years
 250 mg twice daily for children 2 years and above
 Post splenectomy there may be transient or
persistent thrombocytosis. Aspirin 50-100 mg/day
for patients if platelet count >8,00,000/mm3
IMMUNIZATION PRIOR TO SPLENECTOMY
 Pneumcoccal vaccine. 0.5 ml SC
 If child has received a complete primary course PLUS
a single booster dose
 Age<2 years: ( give one dose PCV13 Prevenar13 )
 Age > 2years: ( give one dose PPV 23 Pneumovax 23
revaccinate after 3 years )
 If child has not recieved primary course
 Age 16 months – 5years : give two doses PCV13 Prevenar13
8 weeks apart
 If aged 5-18 years - one dose
 give one dose PPV 23 Pneumovax 23 at least 8 weeks after
the last PCV13 dose , revaccinate after 3 years.
 Meningococcal vaccine:
 Quadravalent meningococcal (Menactra) 0.5
mL IM upper deltoid.
o Children aged 2 through 6 years :Two doses of
Menactra® at least 8 weeks apart, followed by a single
booster dose 3 years later and then a single booster
dose every 5 years
 Children aged 7 years and over and adults through
55 years :Two doses of Menactra® at least 8 weeks
apart, followed by a single booster dose every 5 years
 Haemophilus b conjugate : One dose
regardless of previous vaccination history
RECOMMENDED MONITORING FOR COMPLICATIONS
OF B-THALASSEMIA
Thalassemia
RECOMMENDED MONITORING FOR
COMPLICATIONS OF B-THALASSEMIA
CAUSES OF DEATH
 Congestive heart failure
 Arrhythmia
 Sepsis secondary to increased susceptability to
infection post spleenectomy
 Multiorgan failure due to hemochromatosis
Thalassemia
Thalassemia
LABORATORY
DIAGNOSIS OF
THALASSEMIA
44
 Complete Blood Count (CBC) with red cell
indices and Peripheral Blood Film (PBF)
Examination and reticulocyte count.
 Hb low, total RBC count and Hct decreased
 Thalassemics have uniform microcytosis with
out increase in RDW
 PS of Thalassemia Child
Characteristic bizarre picture of red cells, which
are microcytic, hypochromic, with poikilocytosis,
polychromasia, moderate basophilic stippling, and
fragmented erythrocytes, target cells, and large
number of normoblasts
Thalassemia trait Iron deficiency
anemia
RDW Normal(11.5-14.5) high
RBC count High relative to
hematocrit,Hb
levels
low
Thalassemia major Iron deficiency
anemia
serum Iron
levels
Serum iron high
Sr.ferritin high
TIBC decreased
Transferrin
saturation:
increased
Low
Low
Increased
decreased
 The baseline serum ferritin and liver enzymes
including ALT, AST, bilirubin, lactate dehydrogenase
(LDH) should be measured.
 Full red cell phenoptype [C, c, D, E, e, K, k, Jka,
Jkb, Fya, Fyb, Kpa, Kpb, MNS, Lewis]
 Serologic testing for hepatitis A, B, and C, and HIV
should be performed as baseline measures.
 All first-degree family members should undergo
HLA-typing, if potential future allogeneic
hematopoietic stem cell transplant is considered an
option.
HB ELECTROPHORESIS
LAB DIAGNOSIS ..CONT.
 Osmotic fragility test : decreased
 Urinary urobilinogen: increased (Ehrlich test)
 Stool examination: dark stools, increased
stercobilinogen.
 Radiological changes: seen after 1 year
 X-ray of metacarpals,ribs, vertebra show thinning of cortex
 X-ray of skull shows “hair on end appearance”
 Generalised skeletal osteoporosis
MANAGEMENT OF THALASSEMIA MAJOR
 Comprehensive management includes
the following:
• Confirmation of the diagnosis
• Correction of anemia– Packed red cell transfusions
• Removal of excess iron– Chelation Therapy
• Management of complications – Endocrine and
Cardiac complications
• Pharmacological methods to increase gamma chain
synthesis
• Supportive care
• Curative Treatment– Stem Cell Transplantation
• Future treatment– Gene replacement therapy.
 A team approach includes:
• Pediatric hematologist,
• Pediatrician,
• Blood transfusion specialist
• Endocrinologist,
• Psychologist and
• Social worker, etc
TRANSFUSION THERAPY IN
THALASSEMIA
 Transfusion therapy in thalassemia has
two goals:
• To prevent anemia
• To suppress endogenous erythropoiesis
 Regular Blood Transfusions are Presently the
Mainstay of Treatment of Thalassemia Major.
 Concept of Neocyte transfusion
TRANSFUSION PROTOCOLS
 Palliative– Pretransfusion - Hb level is around < 7 gm%
and mean Hb maintained is < 8.5 gm/dl.
 Hyper Transfusion– Pretransfusion Hb level is
around > 10gm% and mean Hb. Maintained is
> 12 gm%.
 Super Transfusion– Pretransfusion Hb level is
around > 12gm% and mean Hb. Maintained is
>14gm%.
 Moderate– Transfusion- Pretransfusion- Hb level is
around 9-10.5 gm% and mean Hb. Maintained is >12gm
%.
Current recommendation?
TYPE OF TRANSFUSION
 Leukoreduced packed red cell transfusion is
desired type of blood for thalassemic children
 Reduction of leukocytes to 5000000 is considered
adequate.(reduced by 70%)
 It helps in prevention of transfusion reactions and is
achieved by centrifugation;/saline washing/filtration.
METHODS FOR LEUKODEPLETION
 Centrifugation– Packed red cell transfusions
 Saline-cell washing (Triple Saline Washed)
 Deglycerolized–red cells.
 Third generation leucocyte filters
 Irradiated blood cells
BENEFITS OF BLOOD TRANFUSION-
THALASSEMIA
 Improves tissue oxygenation, and prevents chronic
hypoxia
 Improves normal growth and development
 Prevents erythropoiesis thus avoiding expansion of
the bone marrow and extra medullary
erythropoiesis
 Reduces hemolytic facies
 Reduces hepatosplenomegaly and cardiomyopathy
 Reduces gastro-intestinal absorption of iron.
WHEN TO START THE TRANSFUSION
 Blood transfusion is started as soon as diagnosis
firmly established (Except in children > 18 months of
age).
 If age is > 18 months, these children are observed to r/o
Thalassemia Intermedia and if Hb drops < 7 gms%,
regular transfusion started.
 The most ideal way to transfuse thalassemics is using
group and type specific saline washed packed red
cells (HCT - 65 to 75%) that are compatible by direct
antiglobulin test (Coomb’s crossmatched)
RATE AND FREQUENCY OF
TRANSFUSIONS
 10-15 ml/kg of saline washed packed red cells every 3
to 4 weeks.
 Rate not more than 5 ml/kg/hr, however, in patients with
cardiac dysfunction not more than 2-3 ml/kg/hr should
be given.
 Shorter intervals of 2 to 3 weeks are more physiological.
 Average time taken is 3-4 hours
 Approximately 180 ml/kg of red cells are required to be
transfused per year in non-splenectomized,
nonsensitized patients to maintain the hemoglobin
above 10 gms%, whereas splenectomized patients
require 133 ml/kg per year.
 Even without hypersplenism, the requirement is 30%
higher in non-splenectomized patients
COMPLICATIONS OF TRANSFUSION
 NHFTR (Non hemolytic febrile transfusion reaction)
 Allergic reactions
 Acute hemolytic reactions
 Delayed hemolytic reactions
 TRALI-transfusion related acute lung injury
 TACO- transfusion associated circulatory overload
 Alloimmunizaton.
 Transfusion transmitted infections
 Iron overload
 Steps to Prevent These Infections Include
 Screening of blood products.
 All thalassemic children should recieve hepatitis
vaccination if not previously immunised
 Leukodepletion can minimize CMV infection
IRON OVERLOAD AND CHELATION THERAPY
 Iron Overload Occurs in Thalassemic Patients
due to
 Treatment with multiple transfusions
 Ineffective erythropoiesis
 Excessive dietary absorption of iron from gut, to
compensate the large turnover of red cell mass
 Lack of physiologic excretory mechanism for the
excess iron
 The goal of iron chelation is to reduce the iron
store and subsequently maintain at low level
(sr.ferritin less than 1000ng/ml).
INITIATION OF CHELATION THERAPY
 Serum ferritin >1000ng/dl
 Patient has received 15-20 transfusions
 Hepatic iron concentration exceeds 3.2mg/ g dry
weight
CHELATING AGENTS
 Deferoxamine(DFO)
 Route:SC/IV
 Dose: 25-50 mg/kg/day
 Schedule: over 8 to 10 hrs for 5-6 nights a week with the
help of subcutaneous desferal infusion pump
 MOA:chelates loosely bound iron, iron from
ferritin,hemosiderin ,not from transferrin
 Excretion :Urine(80%,urine red)/Feces
 Plasma clearance t1/2: 20 minutes
 Adverse effects Local skin reaction, ototoxicity, infections
,ophthalmic toxicity, skeletal impairment
 Monitoring Long bone films in growing children, annual
eye and ear check-up
CONSIDERATION OF AGGRESSIVE CHELATION
THERAPY
 Severe iron over load
 Persistently very high ferritin value
 Liver iron >15mg/ g dry weight
 Significant cardiac disease
 Cardiac arrhythmias
 Evidence of falling left ventricular function
 Evidence of very severe heart iron loading(MRI T2* <6
ms)
 Prior to bone marrow transplantation when rapid
reversal of iron loading may be desirable
 tab Vitamin C 1hr prior to infusion .
 Deferipone(Kelfer)
 It mobilizes iron from transferrin, ferritin, and
hemosiderin.
 Dose: 75 to 100 mg/kg body weight/day in
three to four divided doses
 Excretion:Urine
 Plasma clearance t1/2:53-166 minutes
 Adverse effects: Agranulocytosis, GIT
disturbances,transaminase elevation,
arthralgias
 Monitoring:Weekly CBC
DEFERIPONE ..CONT
 Drug should be discontinued whenever
 Total count drops to < 3000/mm 3
 Absolute neutophil count drops to < 1000/mm 3
 Zinc deficiency may develop, zinc supplementation
may be necessary
 It should be first line drug for patients not receiving
DFO because of high cost, toxicity or poor
compliance of the later.
 Deferasirox (exjade)
 A novel chelating agent belongs to tridentate tiazole,with
high affinity to iron as Fe+++ and chelates at a ratio of
2:1 (Deferasirox: Iron).
 Dose :20-30 mg/kg/day
 Schedule: daily ,OD
 Excretion:Feces
 Plasma clearance t1/2:1-16 hours
 It should be given approximately same time each day on
an empty stomach 30 minutes prior to food. Tablet
should be dispersed in water/orange /apple juice.
 It is available as 250/500 mg tablet for oral suspension
dispersible tablets
 Monitoring:Monthly RFT, LFT and urine analysis
 Side effects: GI disturbances , rash, renal dysfunction
SHUTTLE HYPOTHESIS
 Co-administration of ICL 670 (Deferasirox) with Inj
DFO has synergic effect and helps in reducing dose
of both the drugs thus improving the compliance
and cost of the treatment as is done with oral
chelation therapy with deriprone and inj. desferal.
 Shuttle effect
also seen with this combination, as ICL 670-
Deferasirox acts as intracellular chelator and DFO as
extracellular.
MANIPULATION OF HBF SWITCHING
 Hydroxyurea
 Histone Deacetylase Inhibitors
 Butyric Acid Analogs
 5-azacytidine,( risk of cancer –not used now)
 Erythropoietin has been tried to induce HbF
production with varying success
STEM CELL TRANSPLANTATION
 This is only the curative therapy available today.
 Sources of stem cells:Bone Marrow, Peripheral
Blood, Cord Blood,Fetal Liver.
 Though expensive, it is cost effective as compared
to yearly cost of regular blood transfusion and
chelation therapy.
 cost 8-10 lakhs.
 Umblical cord stem cells have good results(lower
GVHD, longer engraftment)
GENE THERAPY
Lenti Viral vector derived from Human
Immunodeficiency Virus, where a large fragment of
human beta gene and its locus control region, have
been introduced, though experimental, more
effectiv therapies will become available near future
to cure the disease.
PREVENTION OF THALASSEMIA-CARRIER
SCREENING
 Thalassemia minor or carrier state can be easily
detected in a person by doing simple blood test HbA2 by
hemoglobin electrophoresis or variant machine or
column chromatography
 Prevention includes population education, mass
screening, genetic counseling and antenatal diagnosis
and therapeutic abortion of affected pregnancy
 Carrier detection:The only confirmatory test is HbA2
estimation.
 To conduct an effective mass screening program, the
targeted population should belong to the premarital and
newly married groups, i.e. before they have begun their
families.
ANTENATAL DIAGNOSIS
 When both partners, who are thalassemia minors, plan to
have their baby, they are told to report to their hematologist as
soon as possible after pregnancy is confirmed.
 Chorionic villous sampling (CVS) done between 9th and 11th
week of pregnancy.
 amniocentesis or cordocentesis-16 to 18 weeks of pregnancy.
 Test result:
 ‘Affected’ which means the fetus has thalassemia
major, or
 ‘Unaffected’ meaning that the fetus is either
thalassemia minor or normal.
 Affected fetuses are advised to be terminated and
unaffected fetuses to be continued
REFERENCES
 IAP TEXT BOOK OF PEDIATRICS 5th Ed
 Advances in pediatrics pedicon 2012
 IAP Pediatric Hematology
 Nelson Text Book Pediatrics
 Standards for the Clinical Care of Children and
Adults with Thalassaemia in the UK
 Guidelines for the Clinical Care of Patients with
Thalassemia in Canada
Thank you

More Related Content

What's hot (20)

Beta thalassemia and thalassemia prevention 2021
Beta thalassemia and thalassemia prevention 2021Beta thalassemia and thalassemia prevention 2021
Beta thalassemia and thalassemia prevention 2021
 
Thalassemia
ThalassemiaThalassemia
Thalassemia
 
Microcytic hypochromic anemia
Microcytic hypochromic anemiaMicrocytic hypochromic anemia
Microcytic hypochromic anemia
 
Thalassemia
ThalassemiaThalassemia
Thalassemia
 
Thalassemia syndrome
Thalassemia syndromeThalassemia syndrome
Thalassemia syndrome
 
Aplastic anemia
Aplastic anemiaAplastic anemia
Aplastic anemia
 
Haemoglobinopathies sickle cell anemia
Haemoglobinopathies  sickle cell anemiaHaemoglobinopathies  sickle cell anemia
Haemoglobinopathies sickle cell anemia
 
Thalassemia
Thalassemia Thalassemia
Thalassemia
 
Thalassemia
ThalassemiaThalassemia
Thalassemia
 
Sickle cell anemia
Sickle cell anemiaSickle cell anemia
Sickle cell anemia
 
Sickle cell disease
Sickle cell diseaseSickle cell disease
Sickle cell disease
 
Hemolytic anemia
Hemolytic anemiaHemolytic anemia
Hemolytic anemia
 
Sickle cell
Sickle cell Sickle cell
Sickle cell
 
Sickle cell anaemia
Sickle cell anaemiaSickle cell anaemia
Sickle cell anaemia
 
Thalassemia
ThalassemiaThalassemia
Thalassemia
 
Anemia Causes, Types, Symptoms, Diet, and Treatment
Anemia Causes, Types, Symptoms, Diet, and Treatment Anemia Causes, Types, Symptoms, Diet, and Treatment
Anemia Causes, Types, Symptoms, Diet, and Treatment
 
Diagnosis of Anemia
Diagnosis of Anemia Diagnosis of Anemia
Diagnosis of Anemia
 
Alpha thalassemia
Alpha thalassemiaAlpha thalassemia
Alpha thalassemia
 
Thalassemia
ThalassemiaThalassemia
Thalassemia
 
Leukemia
LeukemiaLeukemia
Leukemia
 

Viewers also liked (20)

Fragile X presentation
Fragile X presentationFragile X presentation
Fragile X presentation
 
Fanconi anemia, syndrome
Fanconi anemia, syndromeFanconi anemia, syndrome
Fanconi anemia, syndrome
 
Phage display and its applications
Phage display and its applicationsPhage display and its applications
Phage display and its applications
 
Fragile x syndrome
Fragile x syndrome Fragile x syndrome
Fragile x syndrome
 
Bio chem presentation on hemophilia
Bio chem presentation on hemophiliaBio chem presentation on hemophilia
Bio chem presentation on hemophilia
 
Diabetes mellitus
Diabetes mellitusDiabetes mellitus
Diabetes mellitus
 
Klinefelter syndrome
Klinefelter syndromeKlinefelter syndrome
Klinefelter syndrome
 
Hemophila pp
Hemophila ppHemophila pp
Hemophila pp
 
Student Work Hemophilia
Student Work HemophiliaStudent Work Hemophilia
Student Work Hemophilia
 
Thalassaemia
ThalassaemiaThalassaemia
Thalassaemia
 
Turners Syndrome
Turners SyndromeTurners Syndrome
Turners Syndrome
 
Biology project
Biology projectBiology project
Biology project
 
Hemophilia
HemophiliaHemophilia
Hemophilia
 
Down Syndrome
Down SyndromeDown Syndrome
Down Syndrome
 
Hemophilia by Suhasis Mondal
Hemophilia by Suhasis MondalHemophilia by Suhasis Mondal
Hemophilia by Suhasis Mondal
 
Turner syndrome
Turner syndromeTurner syndrome
Turner syndrome
 
Genetics sample
Genetics sampleGenetics sample
Genetics sample
 
Turner’s Syndrome Project
Turner’s Syndrome ProjectTurner’s Syndrome Project
Turner’s Syndrome Project
 
Hemophilia
HemophiliaHemophilia
Hemophilia
 
Down Syndrome
Down  SyndromeDown  Syndrome
Down Syndrome
 

Similar to Thalassemia

27 thalassemias
27 thalassemias27 thalassemias
27 thalassemiasDr UAK
 
Introduction to Thalassemia power point..
Introduction to Thalassemia power point..Introduction to Thalassemia power point..
Introduction to Thalassemia power point..AllanIbnSuma
 
hemoglobinopathies-thalassemia-160524164939 (1).pptx
hemoglobinopathies-thalassemia-160524164939 (1).pptxhemoglobinopathies-thalassemia-160524164939 (1).pptx
hemoglobinopathies-thalassemia-160524164939 (1).pptxSaranyaR56
 
(Hematology) alpha and beta thalassemias in english by dr. kalimullah wardak
(Hematology) alpha and beta thalassemias in english by dr. kalimullah wardak(Hematology) alpha and beta thalassemias in english by dr. kalimullah wardak
(Hematology) alpha and beta thalassemias in english by dr. kalimullah wardakKalimullah Wardak
 
Hemoglobinopathy( thalassemia), blood disorders
Hemoglobinopathy( thalassemia), blood disordersHemoglobinopathy( thalassemia), blood disorders
Hemoglobinopathy( thalassemia), blood disordersvedpratap4
 
anemia and thalassemia genetic bases ,the molecular defects and pathophysiol...
 anemia and thalassemia genetic bases ,the molecular defects and pathophysiol... anemia and thalassemia genetic bases ,the molecular defects and pathophysiol...
anemia and thalassemia genetic bases ,the molecular defects and pathophysiol...imam univarsity , college of medicine .
 
Haemoglobinopathies in pregnancy.pptx
Haemoglobinopathies in pregnancy.pptxHaemoglobinopathies in pregnancy.pptx
Haemoglobinopathies in pregnancy.pptxDebendraKumarNaik4
 
Thalassemia_pathogenesis_-_648_Kunj.pdf
Thalassemia_pathogenesis_-_648_Kunj.pdfThalassemia_pathogenesis_-_648_Kunj.pdf
Thalassemia_pathogenesis_-_648_Kunj.pdfGounderKirthika1
 
An Overview of Thalassemia
An Overview of Thalassemia An Overview of Thalassemia
An Overview of Thalassemia Fatima Farid
 
Thalassemia in OBGYN (July 2021)
Thalassemia in OBGYN (July 2021)Thalassemia in OBGYN (July 2021)
Thalassemia in OBGYN (July 2021)OBGYN Notes
 
Thalassemia syndrome
Thalassemia syndromeThalassemia syndrome
Thalassemia syndromeRahul Arya
 

Similar to Thalassemia (20)

Thalassemia
ThalassemiaThalassemia
Thalassemia
 
Thalassemia
ThalassemiaThalassemia
Thalassemia
 
Thalassemia
ThalassemiaThalassemia
Thalassemia
 
27 thalassemias
27 thalassemias27 thalassemias
27 thalassemias
 
Anemia
AnemiaAnemia
Anemia
 
Introduction to Thalassemia power point..
Introduction to Thalassemia power point..Introduction to Thalassemia power point..
Introduction to Thalassemia power point..
 
hemoglobinopathies-thalassemia-160524164939 (1).pptx
hemoglobinopathies-thalassemia-160524164939 (1).pptxhemoglobinopathies-thalassemia-160524164939 (1).pptx
hemoglobinopathies-thalassemia-160524164939 (1).pptx
 
Thalassemia by dr. noman
Thalassemia by dr. nomanThalassemia by dr. noman
Thalassemia by dr. noman
 
Thalassemia ppt.pptx
Thalassemia ppt.pptxThalassemia ppt.pptx
Thalassemia ppt.pptx
 
thalassemia
thalassemiathalassemia
thalassemia
 
(Hematology) alpha and beta thalassemias in english by dr. kalimullah wardak
(Hematology) alpha and beta thalassemias in english by dr. kalimullah wardak(Hematology) alpha and beta thalassemias in english by dr. kalimullah wardak
(Hematology) alpha and beta thalassemias in english by dr. kalimullah wardak
 
Hemoglobinopathy( thalassemia), blood disorders
Hemoglobinopathy( thalassemia), blood disordersHemoglobinopathy( thalassemia), blood disorders
Hemoglobinopathy( thalassemia), blood disorders
 
anemia and thalassemia genetic bases ,the molecular defects and pathophysiol...
 anemia and thalassemia genetic bases ,the molecular defects and pathophysiol... anemia and thalassemia genetic bases ,the molecular defects and pathophysiol...
anemia and thalassemia genetic bases ,the molecular defects and pathophysiol...
 
Haemoglobinopathies in pregnancy.pptx
Haemoglobinopathies in pregnancy.pptxHaemoglobinopathies in pregnancy.pptx
Haemoglobinopathies in pregnancy.pptx
 
Thalassemia_pathogenesis_-_648_Kunj.pdf
Thalassemia_pathogenesis_-_648_Kunj.pdfThalassemia_pathogenesis_-_648_Kunj.pdf
Thalassemia_pathogenesis_-_648_Kunj.pdf
 
An Overview of Thalassemia
An Overview of Thalassemia An Overview of Thalassemia
An Overview of Thalassemia
 
Thalassemia in OBGYN (July 2021)
Thalassemia in OBGYN (July 2021)Thalassemia in OBGYN (July 2021)
Thalassemia in OBGYN (July 2021)
 
Thalassemia syndrome
Thalassemia syndromeThalassemia syndrome
Thalassemia syndrome
 
New sickle copy
New sickle   copyNew sickle   copy
New sickle copy
 
Lecture 7.thalassemia
Lecture 7.thalassemiaLecture 7.thalassemia
Lecture 7.thalassemia
 

Recently uploaded

SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfHongBiThi1
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .Mohamed Rizk Khodair
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfHongBiThi1
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptPradnya Wadekar
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationMedicoseAcademics
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfHongBiThi1
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismusChandrasekar Reddy
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsMedicoseAcademics
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 

Recently uploaded (20)

SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdfSGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
SGK RỐI LOẠN TOAN KIỀM ĐHYHN RẤT HAY VÀ ĐẶC SẮC.pdf
 
Neurological history taking (2024) .
Neurological  history  taking  (2024)  .Neurological  history  taking  (2024)  .
Neurological history taking (2024) .
 
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdfSGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
SGK RỐI LOẠN KALI MÁU CỰC KỲ QUAN TRỌNG.pdf
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
ayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologypptayurvedic formulations herbal drug technologyppt
ayurvedic formulations herbal drug technologyppt
 
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxationPhysiology of Smooth Muscles -Mechanics of contraction and relaxation
Physiology of Smooth Muscles -Mechanics of contraction and relaxation
 
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdfSGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
SGK LEUKEMIA KINH DÒNG BẠCH CÂU HẠT HAY.pdf
 
power point presentation of Clinical evaluation of strabismus
power point presentation of Clinical evaluation  of strabismuspower point presentation of Clinical evaluation  of strabismus
power point presentation of Clinical evaluation of strabismus
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
GOUT UPDATE AHMED YEHIA 2024, case based approach with application of the lat...
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
AUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functionsAUTONOMIC NERVOUS SYSTEM organization and functions
AUTONOMIC NERVOUS SYSTEM organization and functions
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 

Thalassemia

  • 2. OBJECTIVES To know : • Basic features of thalassemia syndromes • Transfusion protocols in thalassemia • Chelation therapy in thalassemia • Supportive care in thalassemic patients • Follow-up guidelines • Hemtopoitic Stem cell transplantation • Future aspects.
  • 3. DEFINITION Thalassemia is a group of inherited disorders of hemoglobin synthesis characterized by a reduced or absent one or more of the globin chains of adult hemoglobin. They characterised by varying degrees of ineffective hematopoiesis and increased hemolysis ICD classification: D-56
  • 4. HEMOGLOBIN A  Fetal Hemoglobin (2 alpha, 2 gamma)  Hemoglobin A2 (2 alpha, 2 delta)  Small amounts in body α αβ β
  • 5. Copyright ©1997 BMJ Publishing Group Ltd.
  • 6. NORMAL HUMAN HAEMOGLOBINS Haemoglobin Structural formula Adult Hb-A 2 2 97% Hb-A2 2 2 1.5-3.2% Fetal Hb-F 2 2 0.5-1% Embryonic Hb-Gower 1 2 2 Hb-Gower 2 2 2 Hb-Portland 2 2
  • 7. GENETIC TYPES OF THALASSEMIA : There are two basic groups of thalassemia.  Alpha (  )Thalassemia In alpha-thalassemia, the alpha genes are deleted; loss of one gene (α-/α) or both genes (α-/α-) from each chromosome 16 may occur, in association with the production of some or no alpha globin chains  Beta (  )Thalassemia In beta-thalassemia defective production usually results from disabling point mutations causing no (β0) or reduced (β-) beta chain production.
  • 8. CHROMOSOMES  Thalassemia is inherited as an autosmal recessive disease.
  • 9. EPIDEMIOLOGY  Recent data indicate that about 7% of the world population is carrier of hemoglobin disorder.  About 100,000 children are born every year world over with the homozygous state for thalassemia. There are around 65,000 - 67,000 thalassemia patients in our country.  In India prevalence of this gene varies, 1-17 % (3.3%).  Common in certain Communities like sindhis, punjabis, khatris, khukrajas, bhanushalies, baniyas, lohanas, kuchies, mahars, kolies, agries, goudas, lingayats .
  • 10. ALPHA THALASSEMIA  Alpha Thalassemia: deficient/absent alpha subunits  Excess beta subunits  Excess gamma subunits newborns  Tetramers formed:  Hemoglobin H adults  Hemoglobin Bart’s newborns  types:  Silent Carrier  Trait (Minor)  Hemoglobin H Disease  Hydrops fetalis(Hb Bart’s)
  • 11. GENETIC BASIS OF ALPHA THALASSEMIA  Encoding genes on chromosome 16 (short arm)  Each cell has 4 copies of the alpha globin gene  Each gene responsible for ¼ production of alpha globin  4 possible mutation states:  Loss of ONE gene  silent carrier  Loss of TWO genes  thalassemia minor (trait)  Loss of THREE genes  Hemoglobin H  Accumulation of beta chains  Association of beta chains in groups of 4  Hemoglobin H  Loss of FOUR genes  Hemoglobin Barts  NO alpha chains produced ∴ only gamma chains present  Association of 4 gamma chains  Hemoglobin Barts
  • 12. CLASSIFICATION & TERMINOLOGY ALPHA THALASSEMIA • Normal / • Silent carrier - / • Minor -/- --/ • Hb H disease --/- • Barts hydrops fetalis --/--
  • 13. CLINICAL OUTCOMES OF ALPHA THALASSEMIA  Silent carriers • asymptomatic • “normal”  Alpha Thalassemia trait • no anemia /mild anemia • microcytosis -unusually small red blood cells due to fewer Hb in RBC  Hb H disease • microcytosis & hemolysis (breakdown of RBC) - results in severe anemia • bone deformities • splenomegaly (enlargement of spleen) • “severe and life threatening” • Golf ball inclusions on micrscopy
  • 14. CLINICAL OUTCOMES OF ALPHA THALASSEMIA  Bart’s Hydrops fetalis • Hb Bart’s • fatal hydrops fetalis - fluid build-up in fetal compartments, leads to death occurs in utero
  • 15. BETA THALASSEMIA  Beta Thalassemia: deficient/absent beta subunits  Commonly found in Mediterranean, Middle East, Asia, and Africa  Three types:  Minor  Intermedia  Major (Cooley anemia)  asymptomatic at birth as HbF functions
  • 16. GENETIC BASIS OF BETA THALASSEMIA  Encoding genes on chromosome 11 (short arm)  Each cell contains 2 copies of beta globin gene  beta globin protein level = alpha globin protein level  Suppression of gene more likely than deletion  2 mutations: beta-+-thal / beta-0-thal  “Loss” of ONE gene  thalassemia minor (trait)  “Loss” of BOTH gene  complex picture  2 beta-+-thal  thalassemia intermedia / thalassemia major  2 beta-0-thal  thalassemia major  Excess of alpha globin chains
  • 17. CLASSIFICATION & TERMINOLOGY BETA THALASSEMIA • Normal / • Minor /0 /+ • Intermedia 0/+ +/+ • Major 0/0 +/
  • 18. CLINICAL OUTCOMES OF BETA THALASSEMIA  Beta Thalassemia minor (trait) • asymptomatic • microcytosis • minor anemia • Elevated HbA2 >3.4%  Beta Thalassemia intermedia . • symptoms similar to Cooley Anemia but less severe  Beta Thalassemia major (Cooley Anemia) • most severe form • moderate to severe anemia • intramedullary hemolysis (RBC die before full development) • peripheral hemolysis & splenomegaly • skeletal abnormalities (overcompensation by bone marrow) • congestive heart failure,pulmonary hypertension
  • 19. PATHOPHYSIOLOGY Disturbance of ratio between Alpha & non alpha globin chain synthesis then absent or decrease production of one or more globin chains Formation of abnormal Hb structures Ineffective erythropoiesis Excessive RBCs Destruction Iron Overload Extra-medullary hematopoiesis
  • 21. SIGNS & SYMPTOMS  Beta Thalassaemia Minor : Usually no signs or symptoms except for a mild persistent anemia not responding to hematinics.  BetaThalassaemia Major : manifests after 6 months 1. Pallor- fatigue, irritability 2. Growth retardation. 3. Recurrent infections 4. Bony abnormalities specially of the facial bones,hemolytic facies, caput quadtratum 5. Enlarged spleen and liver. 6. Delayed sexual development 7. Features of complications .
  • 22. THALASSEMIA COMPLICATIONS  Complications can be grouped as (1) transfusion-transmitted infections, (2) transfusional iron overload, (3) toxicities of iron chelation therapy, and (4) bacterial infections
  • 23. COMPLICTIONS ..CONT..  Cardiac complications  Liver complications  Endocrine complications  Bone complications  Other complications  Infections: yersinia,parvovirus B19  Dental Complications  Growth retardation  Leg ulcers
  • 24. CARDIAC COMPLICATIONS  Cardiac dysfunction(both systolic and diastolic dysfuction)  Arrhythmias  Ferritin greater than 2500 mg/L or a liver iron concentration > 15 mg Fe/g dry weightis associated with high risk of cardiac death in thalassemia  ferritin and liver iron may not correlate with cardiac iron load, cardiac iron can be specifically and reproducibly measured using cardiac MRI T2*. Cardiac MRI T2* less than 20 ms correlates with a progressive and significant decline in LVEF
  • 25. CARDIAC COMPLICATIONS CONT..  Monitoring: 6 monthly cardiac physical examination, cardiac function yearly starting at age of 10 years, if history suggestive of arrhythmias ECG, 24-hour Holter monitoring should be done.  Chelation therapy to reduce high iron load lowers the likelihood of developing cardiac dysfunction
  • 26. CARDIAC COMPLICATIONS..CONT Cardiac MRI T2 Cardiac iron load Cardiac function intervention values greater than 20 ms not usually associated with significant iron load not usually associated with cardiac dysfunction compliance and importance of chelation stressed values between 10 and 20 ms significant cardiac iron deposition a risk of eventual cardiac decompensation more aggressive chelation program should be implemented values < 10 ms Very high cardiac iron load significant risk of more immediate cardiac decompensation without aggressive Aggressive chelation therapy should be started immediately and cardiac function
  • 27. CARDIAC COMPLICATIONS..CONT  Where cardiac MRI T2* is not available, • chelation decisions should be based on ferritin, LIC and cardiac function assessment  Patients with ferritin > 2500 mg/ml and LIC >15g Fe/g dry weight should be chelated more aggressively.  those with ferritin < 2500 mg/ml and LIC 7 – 15 g Fe/g dry weight should have chelation adjusted accordingly and compliance encouraged.  Cardiologic intervention and management for heart failure and arrhythmia should follow cardiology standards apart from aggressive chelation
  • 28. LIVER COMPLICATIONS  includes- transfusion-related viral hepatitis (Hepatitis B, C), iron overload, drug toxicity, and biliary disease due to gallstones.  Liver enzymes should be monitored routinely.  Liver iron concentration should be monitored routinely and chelation therapy initiated and adjusted to reduce complications of iron overload.  In the presence of elevated liver iron, liver fibrosis, and cirrhosis may be accelerated by alcohol, liver- toxic drugs, and untreated viral hepatitis, Limit such exposure.
  • 29. ENDOCRINE COMPLICATIONS  Iron overload is responsible for dysfunction of many of endocrine glands like thyroid, parathyroid pituitary gland, gonads and pancreas.  These include-  short stature (34%),  delayed puberty, hypogonadotropic hypogonadism (35 – 55%),  hypothyroidism (10%),  hypoparathyroidism (4%), and  diabetes mellitus (5.6 – 20%)
  • 30. ENDOCRINE COMPLICATIONS - INTERVENTIONS  Short stature-  The diagnosis of growth hormone deficiency, other hormonal or nutritional deficiencies or deferoxamine toxicity should be considered  Growth hormone stimulation testing should be done and, if indicated, growth hormone therapy started  Hypothyroidism  TSH levels should be measured annually beginning at 12 years of age since hypothyroidism often develops after adolescence.  Hypothyroidism should be treated with thyroid hormone replacement.
  • 31. ENDOCRINE COMPLICATIONS - INTERVENTIONS  Impaired Glucose Tolerance and Diabetes  Improvement of iron load with adequate combination chelation therapy may decrease insulin resistance and decrease glucose intolerance  Impaired glucose tolerance and diabetes should be managed as per diabetes protocols with emphasis on glycemic control, diet, exercise, and management of complications.
  • 32. ENDOCRINE COMPLICATIONS - INTERVENTIONS  Delayed Puberty and Hypogonadism  most common endocrine complication  all children should be assessed yearly from the age of 10 years  All patients with delayed puberty or hypogonadism should receive appropriate investigations including bone age and hormonal assessments, hormonal replacement therapy, and subsequent follow-up by an endocrinologist  Hypoparathyroidism  All patients over the age of 12 years should have calcium and phosphate levels checked at least every 6 months.  If these are abnormal, parathyroid hormone level should be measured. Hypoparathyroidism should be managed as per endocrine standards
  • 33. BONE COMPLICATIONS  Bone disorders are common and multifactorial in patients with thalassemia .  Related to inadequate transfusion, iron-overload, over-chelation, and other endocrine factors contribute to the development of osteopenia and osteoporosis  Interventions:  Adequate blood transfusions  Adequate chelation therapy should be maintained  No Over-chelation  Hormone replacement therapy  Calcitonin,bisphosphonates  Diet rich in calcium and vitamin D
  • 34. HYPERSPLENISM- SPLENECTOMY  Indictions of splenectomy  An increase in the yearly requirement of packed cells more than 1.5 times the basal requirement, i.e. packed cell 200 to 220 cc per kg/ year.  Massive splenic enlargement posing risk of splenic rupture, or when it is associated with left upper quadrant pain or erly satiety  Presence of leukopenia or thrombocytopenia due to hyperspleenism  Splenectomy should be delayed till the patientis 5 years of age as there is risk of overwhleming sepsis below this age
  • 35.  Risk of post-splenectomy serious infections can be reduced by:  Immunization against pneumococcal, meningococcal, and Hib and salmonella typhi infection atleast 3 weeks before splenectomy  Chemoprophylaxis with oral penicillin,  125 mg twice daily for children upto 2 years  250 mg twice daily for children 2 years and above  Post splenectomy there may be transient or persistent thrombocytosis. Aspirin 50-100 mg/day for patients if platelet count >8,00,000/mm3
  • 36. IMMUNIZATION PRIOR TO SPLENECTOMY  Pneumcoccal vaccine. 0.5 ml SC  If child has received a complete primary course PLUS a single booster dose  Age<2 years: ( give one dose PCV13 Prevenar13 )  Age > 2years: ( give one dose PPV 23 Pneumovax 23 revaccinate after 3 years )  If child has not recieved primary course  Age 16 months – 5years : give two doses PCV13 Prevenar13 8 weeks apart  If aged 5-18 years - one dose  give one dose PPV 23 Pneumovax 23 at least 8 weeks after the last PCV13 dose , revaccinate after 3 years.
  • 37.  Meningococcal vaccine:  Quadravalent meningococcal (Menactra) 0.5 mL IM upper deltoid. o Children aged 2 through 6 years :Two doses of Menactra® at least 8 weeks apart, followed by a single booster dose 3 years later and then a single booster dose every 5 years  Children aged 7 years and over and adults through 55 years :Two doses of Menactra® at least 8 weeks apart, followed by a single booster dose every 5 years  Haemophilus b conjugate : One dose regardless of previous vaccination history
  • 38. RECOMMENDED MONITORING FOR COMPLICATIONS OF B-THALASSEMIA
  • 41. CAUSES OF DEATH  Congestive heart failure  Arrhythmia  Sepsis secondary to increased susceptability to infection post spleenectomy  Multiorgan failure due to hemochromatosis
  • 45.  Complete Blood Count (CBC) with red cell indices and Peripheral Blood Film (PBF) Examination and reticulocyte count.  Hb low, total RBC count and Hct decreased  Thalassemics have uniform microcytosis with out increase in RDW  PS of Thalassemia Child Characteristic bizarre picture of red cells, which are microcytic, hypochromic, with poikilocytosis, polychromasia, moderate basophilic stippling, and fragmented erythrocytes, target cells, and large number of normoblasts
  • 46. Thalassemia trait Iron deficiency anemia RDW Normal(11.5-14.5) high RBC count High relative to hematocrit,Hb levels low Thalassemia major Iron deficiency anemia serum Iron levels Serum iron high Sr.ferritin high TIBC decreased Transferrin saturation: increased Low Low Increased decreased
  • 47.  The baseline serum ferritin and liver enzymes including ALT, AST, bilirubin, lactate dehydrogenase (LDH) should be measured.  Full red cell phenoptype [C, c, D, E, e, K, k, Jka, Jkb, Fya, Fyb, Kpa, Kpb, MNS, Lewis]  Serologic testing for hepatitis A, B, and C, and HIV should be performed as baseline measures.  All first-degree family members should undergo HLA-typing, if potential future allogeneic hematopoietic stem cell transplant is considered an option.
  • 49. LAB DIAGNOSIS ..CONT.  Osmotic fragility test : decreased  Urinary urobilinogen: increased (Ehrlich test)  Stool examination: dark stools, increased stercobilinogen.  Radiological changes: seen after 1 year  X-ray of metacarpals,ribs, vertebra show thinning of cortex  X-ray of skull shows “hair on end appearance”  Generalised skeletal osteoporosis
  • 50. MANAGEMENT OF THALASSEMIA MAJOR  Comprehensive management includes the following: • Confirmation of the diagnosis • Correction of anemia– Packed red cell transfusions • Removal of excess iron– Chelation Therapy • Management of complications – Endocrine and Cardiac complications • Pharmacological methods to increase gamma chain synthesis • Supportive care • Curative Treatment– Stem Cell Transplantation • Future treatment– Gene replacement therapy.
  • 51.  A team approach includes: • Pediatric hematologist, • Pediatrician, • Blood transfusion specialist • Endocrinologist, • Psychologist and • Social worker, etc
  • 52. TRANSFUSION THERAPY IN THALASSEMIA  Transfusion therapy in thalassemia has two goals: • To prevent anemia • To suppress endogenous erythropoiesis  Regular Blood Transfusions are Presently the Mainstay of Treatment of Thalassemia Major.  Concept of Neocyte transfusion
  • 53. TRANSFUSION PROTOCOLS  Palliative– Pretransfusion - Hb level is around < 7 gm% and mean Hb maintained is < 8.5 gm/dl.  Hyper Transfusion– Pretransfusion Hb level is around > 10gm% and mean Hb. Maintained is > 12 gm%.  Super Transfusion– Pretransfusion Hb level is around > 12gm% and mean Hb. Maintained is >14gm%.  Moderate– Transfusion- Pretransfusion- Hb level is around 9-10.5 gm% and mean Hb. Maintained is >12gm %. Current recommendation?
  • 54. TYPE OF TRANSFUSION  Leukoreduced packed red cell transfusion is desired type of blood for thalassemic children  Reduction of leukocytes to 5000000 is considered adequate.(reduced by 70%)  It helps in prevention of transfusion reactions and is achieved by centrifugation;/saline washing/filtration.
  • 55. METHODS FOR LEUKODEPLETION  Centrifugation– Packed red cell transfusions  Saline-cell washing (Triple Saline Washed)  Deglycerolized–red cells.  Third generation leucocyte filters  Irradiated blood cells
  • 56. BENEFITS OF BLOOD TRANFUSION- THALASSEMIA  Improves tissue oxygenation, and prevents chronic hypoxia  Improves normal growth and development  Prevents erythropoiesis thus avoiding expansion of the bone marrow and extra medullary erythropoiesis  Reduces hemolytic facies  Reduces hepatosplenomegaly and cardiomyopathy  Reduces gastro-intestinal absorption of iron.
  • 57. WHEN TO START THE TRANSFUSION  Blood transfusion is started as soon as diagnosis firmly established (Except in children > 18 months of age).  If age is > 18 months, these children are observed to r/o Thalassemia Intermedia and if Hb drops < 7 gms%, regular transfusion started.  The most ideal way to transfuse thalassemics is using group and type specific saline washed packed red cells (HCT - 65 to 75%) that are compatible by direct antiglobulin test (Coomb’s crossmatched)
  • 58. RATE AND FREQUENCY OF TRANSFUSIONS  10-15 ml/kg of saline washed packed red cells every 3 to 4 weeks.  Rate not more than 5 ml/kg/hr, however, in patients with cardiac dysfunction not more than 2-3 ml/kg/hr should be given.  Shorter intervals of 2 to 3 weeks are more physiological.  Average time taken is 3-4 hours  Approximately 180 ml/kg of red cells are required to be transfused per year in non-splenectomized, nonsensitized patients to maintain the hemoglobin above 10 gms%, whereas splenectomized patients require 133 ml/kg per year.  Even without hypersplenism, the requirement is 30% higher in non-splenectomized patients
  • 59. COMPLICATIONS OF TRANSFUSION  NHFTR (Non hemolytic febrile transfusion reaction)  Allergic reactions  Acute hemolytic reactions  Delayed hemolytic reactions  TRALI-transfusion related acute lung injury  TACO- transfusion associated circulatory overload  Alloimmunizaton.  Transfusion transmitted infections  Iron overload  Steps to Prevent These Infections Include  Screening of blood products.  All thalassemic children should recieve hepatitis vaccination if not previously immunised  Leukodepletion can minimize CMV infection
  • 60. IRON OVERLOAD AND CHELATION THERAPY  Iron Overload Occurs in Thalassemic Patients due to  Treatment with multiple transfusions  Ineffective erythropoiesis  Excessive dietary absorption of iron from gut, to compensate the large turnover of red cell mass  Lack of physiologic excretory mechanism for the excess iron  The goal of iron chelation is to reduce the iron store and subsequently maintain at low level (sr.ferritin less than 1000ng/ml).
  • 61. INITIATION OF CHELATION THERAPY  Serum ferritin >1000ng/dl  Patient has received 15-20 transfusions  Hepatic iron concentration exceeds 3.2mg/ g dry weight
  • 62. CHELATING AGENTS  Deferoxamine(DFO)  Route:SC/IV  Dose: 25-50 mg/kg/day  Schedule: over 8 to 10 hrs for 5-6 nights a week with the help of subcutaneous desferal infusion pump  MOA:chelates loosely bound iron, iron from ferritin,hemosiderin ,not from transferrin  Excretion :Urine(80%,urine red)/Feces  Plasma clearance t1/2: 20 minutes  Adverse effects Local skin reaction, ototoxicity, infections ,ophthalmic toxicity, skeletal impairment  Monitoring Long bone films in growing children, annual eye and ear check-up
  • 63. CONSIDERATION OF AGGRESSIVE CHELATION THERAPY  Severe iron over load  Persistently very high ferritin value  Liver iron >15mg/ g dry weight  Significant cardiac disease  Cardiac arrhythmias  Evidence of falling left ventricular function  Evidence of very severe heart iron loading(MRI T2* <6 ms)  Prior to bone marrow transplantation when rapid reversal of iron loading may be desirable  tab Vitamin C 1hr prior to infusion .
  • 64.  Deferipone(Kelfer)  It mobilizes iron from transferrin, ferritin, and hemosiderin.  Dose: 75 to 100 mg/kg body weight/day in three to four divided doses  Excretion:Urine  Plasma clearance t1/2:53-166 minutes  Adverse effects: Agranulocytosis, GIT disturbances,transaminase elevation, arthralgias  Monitoring:Weekly CBC
  • 65. DEFERIPONE ..CONT  Drug should be discontinued whenever  Total count drops to < 3000/mm 3  Absolute neutophil count drops to < 1000/mm 3  Zinc deficiency may develop, zinc supplementation may be necessary  It should be first line drug for patients not receiving DFO because of high cost, toxicity or poor compliance of the later.
  • 66.  Deferasirox (exjade)  A novel chelating agent belongs to tridentate tiazole,with high affinity to iron as Fe+++ and chelates at a ratio of 2:1 (Deferasirox: Iron).  Dose :20-30 mg/kg/day  Schedule: daily ,OD  Excretion:Feces  Plasma clearance t1/2:1-16 hours  It should be given approximately same time each day on an empty stomach 30 minutes prior to food. Tablet should be dispersed in water/orange /apple juice.  It is available as 250/500 mg tablet for oral suspension dispersible tablets  Monitoring:Monthly RFT, LFT and urine analysis  Side effects: GI disturbances , rash, renal dysfunction
  • 67. SHUTTLE HYPOTHESIS  Co-administration of ICL 670 (Deferasirox) with Inj DFO has synergic effect and helps in reducing dose of both the drugs thus improving the compliance and cost of the treatment as is done with oral chelation therapy with deriprone and inj. desferal.  Shuttle effect also seen with this combination, as ICL 670- Deferasirox acts as intracellular chelator and DFO as extracellular.
  • 68. MANIPULATION OF HBF SWITCHING  Hydroxyurea  Histone Deacetylase Inhibitors  Butyric Acid Analogs  5-azacytidine,( risk of cancer –not used now)  Erythropoietin has been tried to induce HbF production with varying success
  • 69. STEM CELL TRANSPLANTATION  This is only the curative therapy available today.  Sources of stem cells:Bone Marrow, Peripheral Blood, Cord Blood,Fetal Liver.  Though expensive, it is cost effective as compared to yearly cost of regular blood transfusion and chelation therapy.  cost 8-10 lakhs.  Umblical cord stem cells have good results(lower GVHD, longer engraftment)
  • 70. GENE THERAPY Lenti Viral vector derived from Human Immunodeficiency Virus, where a large fragment of human beta gene and its locus control region, have been introduced, though experimental, more effectiv therapies will become available near future to cure the disease.
  • 71. PREVENTION OF THALASSEMIA-CARRIER SCREENING  Thalassemia minor or carrier state can be easily detected in a person by doing simple blood test HbA2 by hemoglobin electrophoresis or variant machine or column chromatography  Prevention includes population education, mass screening, genetic counseling and antenatal diagnosis and therapeutic abortion of affected pregnancy  Carrier detection:The only confirmatory test is HbA2 estimation.  To conduct an effective mass screening program, the targeted population should belong to the premarital and newly married groups, i.e. before they have begun their families.
  • 72. ANTENATAL DIAGNOSIS  When both partners, who are thalassemia minors, plan to have their baby, they are told to report to their hematologist as soon as possible after pregnancy is confirmed.  Chorionic villous sampling (CVS) done between 9th and 11th week of pregnancy.  amniocentesis or cordocentesis-16 to 18 weeks of pregnancy.  Test result:  ‘Affected’ which means the fetus has thalassemia major, or  ‘Unaffected’ meaning that the fetus is either thalassemia minor or normal.  Affected fetuses are advised to be terminated and unaffected fetuses to be continued
  • 73. REFERENCES  IAP TEXT BOOK OF PEDIATRICS 5th Ed  Advances in pediatrics pedicon 2012  IAP Pediatric Hematology  Nelson Text Book Pediatrics  Standards for the Clinical Care of Children and Adults with Thalassaemia in the UK  Guidelines for the Clinical Care of Patients with Thalassemia in Canada